Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ephedrine + guaifenesin is an over-the-counter (OTC) combination medication used for the temporary relief of mild symptoms of intermittent asthma, including wheezing, chest tightness, and shortness of breath. It contains two active ingredients: ephedrine, a sympathomimetic amine that acts as a bronchodilator by stimulating alpha and beta-adrenergic receptors to relax bronchial smooth muscle, and guaifenesin, an expectorant that helps thin and loosen bronchial secretions to make coughs more productive. This combination is typically administered as oral tablets. While it provides symptomatic relief, it is not intended for the treatment of severe or persistent asthma. The drug is available as a generic product and is marketed under well-known brand names such as Bronkaid and Primatene Tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ephedrine + guaifenesin.